Published in Antimicrob Agents Chemother on December 01, 2001
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet (2009) 5.30
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med (2014) 2.42
Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2003) 2.34
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med (2005) 2.21
Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother (2002) 2.03
Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother (2006) 1.81
Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother (2003) 1.71
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother (2008) 1.50
Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med (2005) 1.31
Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother (2008) 1.13
In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2004) 1.10
Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother (2009) 1.08
Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother (2008) 1.06
Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One (2013) 1.04
Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice. Antimicrob Agents Chemother (2003) 1.01
Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice. Antimicrob Agents Chemother (2005) 0.82
New regimens for reducing the duration of the treatment of drug-susceptible pulmonary tuberculosis. Drug Dev Res (2011) 0.80
Effects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-Analysis. PLoS One (2015) 0.79
Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program. Trials (2013) 0.76
[Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation]. Rev Tuberc Pneumol (Paris) (1963) 5.58
Statistics in practice. Comparing the means of several groups. N Engl J Med (1985) 4.79
In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1998) 3.02
Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother (1993) 2.97
Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother (1999) 2.54
Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother (1999) 2.37
Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis (1993) 2.07
Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother (1999) 1.67
Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob Agents Chemother (1997) 1.46
Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med (1994) 1.35
Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am J Respir Crit Care Med (1998) 1.30
Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone. J Antimicrob Chemother (1999) 1.24
Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. Am J Respir Crit Care Med (1998) 1.20
Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens. Am J Respir Crit Care Med (2000) 1.13
Late results of long-term intermittent chemotherapy of advanced, murine tuberculosis: limits of the murine model. Tubercle (1967) 0.98
Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet (1994) 9.20
Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis (1991) 4.74
GRIP: a synaptic PDZ domain-containing protein that interacts with AMPA receptors. Nature (1997) 4.49
Elevated circulating cardiotrophin-1 in heart failure: relationship with parameters of left ventricular systolic dysfunction. Clin Sci (Lond) (2000) 4.34
Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron (1996) 4.00
Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother (2005) 3.81
Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother (1992) 3.72
Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis (1989) 3.69
The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. Am Rev Respir Dis (1987) 3.48
The challenge of tuberculosis: statements on global control and prevention. Lancet (1995) 3.19
In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1998) 3.02
Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother (1993) 2.97
Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis (2003) 2.92
Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother (2005) 2.74
Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis (2007) 2.68
USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med (1990) 2.68
Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle (1991) 2.59
Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis (1992) 2.55
Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. Antimicrob Agents Chemother (1990) 2.46
Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents Chemother (1994) 2.34
Tuberculous meningitis in France in 1990: characteristics and impact of BCG vaccination. Tuber Lung Dis (1994) 2.21
Recent advances in the chemotherapy of leprosy. Lepr Rev (1990) 2.11
Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob Agents Chemother (1999) 2.09
Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. Antimicrob Agents Chemother (1991) 2.08
Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis (1993) 2.07
Impact of BCG on tuberculous meningitis in France in 1990. Lancet (1992) 1.97
Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother (2006) 1.97
Prevalence of enteric pathogens in homosexual men with and without acquired immunodeficiency syndrome. Gastroenterology (1988) 1.93
The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc (1978) 1.92
Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int J Tuberc Lung Dis (2006) 1.91
Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother (2001) 1.90
[Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)]. Pathol Biol (Paris) (1982) 1.90
Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis (2004) 1.89
In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1995) 1.80
Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother (2000) 1.79
In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. Tubercle (1991) 1.77
Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrob Agents Chemother (1991) 1.77
Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin Chest Med (1980) 1.76
Redistribution and stabilization of cell surface glutamate receptors during synapse formation. J Neurosci (1997) 1.73
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS (2001) 1.73
Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. Tuber Lung Dis (1994) 1.71
In sickness and in health: Corneal epithelial stem cell biology, pathology and therapy. Exp Eye Res (2009) 1.71
Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group. Int J Lepr Other Mycobact Dis (1995) 1.71
A prospective study of protected bronchoalveolar lavage in the diagnosis of nosocomial pneumonia. Anesthesiology (1989) 1.64
Rocky Mountain spotted fever: epidemiology of an increasing problem. Ann Intern Med (1976) 1.63
Diagnosis of heart failure using urinary natriuretic peptides. Clin Sci (Lond) (2004) 1.62
Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis (1994) 1.60
Preparation by two-dimensional electrophoresis of proteins for antibody production: antibodies against proteins whose synthesis is reduced by auxin in tobacco mesophyll protoplasts. Electrophoresis (1988) 1.55
Outbreak of tuberculosis in a migrants' shelter, Paris, France, 2002. Int J Tuberc Lung Dis (2005) 1.50
A blind study of the polymerase chain reaction for the detection of Mycobacterium tuberculosis DNA. Azay Mycobacteria Study Group. Tuber Lung Dis (1996) 1.49
Mycobacterial lung disease in cystic fibrosis: a prospective study. Pediatr Infect Dis J (1997) 1.49
A 10-year prospective surveillance of Mycobacterium tuberculosis drug resistance in France 1995-2004. Eur Respir J (2007) 1.49
Splice variant-specific interaction of the NMDA receptor subunit NR1 with neuronal intermediate filaments. J Neurosci (1998) 1.46
Why multidrug therapy for multibacillary leprosy can be shortened to 12 months. Lepr Rev (1998) 1.46
Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob Agents Chemother (1997) 1.46
Leprosy and BCG in southern Vietnam. Lancet (1990) 1.44
Results of blood cultures for detection of mycobacteria in AIDS patients. Tubercle (1989) 1.43
Ofloxacin for the treatment of leprosy. Acta Leprol (1991) 1.41
Adverse effects of rifampin. Rev Infect Dis (1983) 1.40
Trend in HIV prevalence among tuberculosis patients in Tanzania, 1991-1998. Int J Tuberc Lung Dis (2001) 1.40
Tuberculosis elimination: are we willing to pay the price? Am J Respir Crit Care Med (2001) 1.38
Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med (1994) 1.35
Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. Oncogene (2012) 1.34
A case-control study for multidrug-resistant tuberculosis: risk factors in four European countries. Microb Drug Resist (2005) 1.33
Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med (1993) 1.32
An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993. AIDS (1996) 1.32
Characterization of excitatory amino acid receptors expressed by embryonic chick motoneurons in vitro. J Neurosci (1986) 1.32
Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am J Respir Crit Care Med (1998) 1.30
Iron and Mycobacterium tuberculosis infection. J Clin Virol (2001) 1.28
Mycobacterium xenopi spinal infections after discovertebral surgery: investigation and screening of a large outbreak. Lancet (2001) 1.28
Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae. Lancet (1997) 1.28
CCK independently activates intracellular trypsinogen and NF-kappaB in rat pancreatic acinar cells. Am J Physiol Cell Physiol (2001) 1.24
Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy. Antimicrob Agents Chemother (1992) 1.22
Is PCR a useful tool for the diagnosis of tuberculosis in 1995? Tuber Lung Dis (1995) 1.22
Swine-like influenza virus infection in a Wisconsin farm family. J Infect Dis (1977) 1.20
On the mechanism of acetylcholine receptor accumulation at newly formed synapses on chick myotubes. J Neurosci (1985) 1.19